166 related articles for article (PubMed ID: 21705369)
1. The antibody-mediated targeted delivery of interleukin-10 inhibits endometriosis in a syngeneic mouse model.
Schwager K; Bootz F; Imesch P; Kaspar M; Trachsel E; Neri D
Hum Reprod; 2011 Sep; 26(9):2344-52. PubMed ID: 21705369
[TBL] [Abstract][Full Text] [Related]
2. Antibody-mediated delivery of interleukin 4 to the neo-vasculature reduces chronic skin inflammation.
Hemmerle T; Zgraggen S; Matasci M; Halin C; Detmar M; Neri D
J Dermatol Sci; 2014 Nov; 76(2):96-103. PubMed ID: 25190364
[TBL] [Abstract][Full Text] [Related]
3. The Targeted Delivery of Interleukin 4 Inhibits Development of Endometriotic Lesions in a Mouse Model.
Quattrone F; Sanchez AM; Pannese M; Hemmerle T; Viganò P; Candiani M; Petraglia F; Neri D; Panina-Bordignon P
Reprod Sci; 2015 Sep; 22(9):1143-52. PubMed ID: 25850899
[TBL] [Abstract][Full Text] [Related]
4. Preclinical evaluation of IL2-based immunocytokines supports their use in combination with dacarbazine, paclitaxel and TNF-based immunotherapy.
Pretto F; Elia G; Castioni N; Neri D
Cancer Immunol Immunother; 2014 Sep; 63(9):901-10. PubMed ID: 24893857
[TBL] [Abstract][Full Text] [Related]
5. Targeted delivery of interleukin-10 to chronic cardiac allograft rejection using a human antibody specific to the extra domain A of fibronectin.
Franz M; Doll F; Grün K; Richter P; Köse N; Ziffels B; Schubert H; Figulla HR; Jung C; Gummert J; Renner A; Neri D; Berndt A
Int J Cardiol; 2015 Sep; 195():311-22. PubMed ID: 26056964
[TBL] [Abstract][Full Text] [Related]
6. Tumor-targeting properties of novel immunocytokines based on murine IL1β and IL6.
Hess C; Neri D
Protein Eng Des Sel; 2014 Jun; 27(6):207-13. PubMed ID: 24795343
[TBL] [Abstract][Full Text] [Related]
7. Selective imaging of chronic cardiac rejection using a human antibody specific to the alternatively spliced EDA domain of fibronectin.
Franz M; Hilger I; Grün K; Kossatz S; Richter P; Petersen I; Jung C; Gummert J; Figulla HR; Kosmehl H; Neri D; Berndt A; Renner A
J Heart Lung Transplant; 2013 Jun; 32(6):641-50. PubMed ID: 23701854
[TBL] [Abstract][Full Text] [Related]
8. Preclinical characterization of DEKAVIL (F8-IL10), a novel clinical-stage immunocytokine which inhibits the progression of collagen-induced arthritis.
Schwager K; Kaspar M; Bootz F; Marcolongo R; Paresce E; Neri D; Trachsel E
Arthritis Res Ther; 2009; 11(5):R142. PubMed ID: 19781067
[TBL] [Abstract][Full Text] [Related]
9. Antibody-based targeting of interferon-alpha to the tumor neovasculature: a critical evaluation.
Frey K; Zivanovic A; Schwager K; Neri D
Integr Biol (Camb); 2011 Apr; 3(4):468-78. PubMed ID: 21225052
[TBL] [Abstract][Full Text] [Related]
10. The antibody-based delivery of interleukin-12 to the tumor neovasculature eradicates murine models of cancer in combination with paclitaxel.
Pasche N; Wulhfard S; Pretto F; Carugati E; Neri D
Clin Cancer Res; 2012 Aug; 18(15):4092-103. PubMed ID: 22693354
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic efficacy of the F8-IL2 immunocytokine in a metastatic mouse model of lung adenocarcinoma.
Wieckowski S; Hemmerle T; Prince SS; Schlienger BD; Hillinger S; Neri D; Zippelius A
Lung Cancer; 2015 Apr; 88(1):9-15. PubMed ID: 25682318
[TBL] [Abstract][Full Text] [Related]
12. Murine analogues of etanercept and of F8-IL10 inhibit the progression of collagen-induced arthritis in the mouse.
Doll F; Schwager K; Hemmerle T; Neri D
Arthritis Res Ther; 2013 Sep; 15(5):R138. PubMed ID: 24289726
[TBL] [Abstract][Full Text] [Related]
13. The immunocytokine F8-IL2 improves the therapeutic performance of sunitinib in a mouse model of renal cell carcinoma.
Frey K; Schliemann C; Schwager K; Giavazzi R; Johannsen M; Neri D
J Urol; 2010 Dec; 184(6):2540-8. PubMed ID: 21030045
[TBL] [Abstract][Full Text] [Related]
14. A high-affinity human monoclonal antibody specific to the alternatively spliced EDA domain of fibronectin efficiently targets tumor neo-vasculature in vivo.
Villa A; Trachsel E; Kaspar M; Schliemann C; Sommavilla R; Rybak JN; Rösli C; Borsi L; Neri D
Int J Cancer; 2008 Jun; 122(11):2405-13. PubMed ID: 18271006
[TBL] [Abstract][Full Text] [Related]
15. Antibody-mediated delivery of interleukin-2 to the stroma of breast cancer strongly enhances the potency of chemotherapy.
Mårlind J; Kaspar M; Trachsel E; Sommavilla R; Hindle S; Bacci C; Giovannoni L; Neri D
Clin Cancer Res; 2008 Oct; 14(20):6515-24. PubMed ID: 18927291
[TBL] [Abstract][Full Text] [Related]
16. Paclitaxel enhances therapeutic efficacy of the F8-IL2 immunocytokine to EDA-fibronectin-positive metastatic human melanoma xenografts.
Moschetta M; Pretto F; Berndt A; Galler K; Richter P; Bassi A; Oliva P; Micotti E; Valbusa G; Schwager K; Kaspar M; Trachsel E; Kosmehl H; Bani MR; Neri D; Giavazzi R
Cancer Res; 2012 Apr; 72(7):1814-24. PubMed ID: 22392081
[TBL] [Abstract][Full Text] [Related]
17. Cloning and characterization of novel tumor-targeting immunocytokines based on murine IL7.
Pasche N; Woytschak J; Wulhfard S; Villa A; Frey K; Neri D
J Biotechnol; 2011 Jun; 154(1):84-92. PubMed ID: 21527292
[TBL] [Abstract][Full Text] [Related]
18. Alternatively Spliced EDA Domain of Fibronectin Is a Target for Pharmacodelivery Applications in Inflammatory Bowel Disease.
Bootz F; Schmid AS; Neri D
Inflamm Bowel Dis; 2015 Aug; 21(8):1908-17. PubMed ID: 25993691
[TBL] [Abstract][Full Text] [Related]
19. The antibody-mediated targeted delivery of interleukin-13 to syngeneic murine tumors mediates a potent anticancer activity.
Hess C; Neri D
Cancer Immunol Immunother; 2015 May; 64(5):635-44. PubMed ID: 25722088
[TBL] [Abstract][Full Text] [Related]
20. Potentiation of PD-L1 blockade with a potency-matched dual cytokine-antibody fusion protein leads to cancer eradication in BALB/c-derived tumors but not in other mouse strains.
De Luca R; Neri D
Cancer Immunol Immunother; 2018 Sep; 67(9):1381-1391. PubMed ID: 29971465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]